Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy

J Clin Virol. 2003 Feb;26(2):247-63. doi: 10.1016/s1386-6532(02)00123-3.

Abstract

Defective immunological function of cells of the macrophage lineage contributes considerably to the pathogenesis of HIV-1 infection. Impairment of phagocytosis of opportunistic pathogens such as Mycobacterium avium complex (MAC), Pneumocystis carinii, Toxoplasma gondii or Candida albicans by peripheral blood monocytes, tissue macrophages and monocyte-derived macrophages following in vivo and in vitro HIV-1 infection is well documented. The development of opportunistic infections due to these pathogens in HIV-infected individuals at late stages of disease is attributed to defective monocyte/macrophage function. The mechanisms whereby HIV-1 impairs phagocytosis are not well known. A number of phagocytic receptors normally mediate engulfment of specific opportunistic pathogens by cells of macrophage lineage; distinct mechanisms are triggered by pathogen-receptor binding to promote cytoskeletal rearrangements and engulfment. This review focuses on the signalling events occurring during Fcgamma receptor- and complement receptor-mediated phagocytosis, and considers the mechanisms by which HIV-1 inhibits those signalling events. Since macrophage function is enhanced by cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interferon-gamma (IFN-gamma), the use of these immunomodulators is of potential interest as adjunctive immunotherapy in immunosuppressed individuals. In this review we present examples of clinical applications of GM-CSF and IFN-gamma therapy for the treatment of opportunistic infections in HIV-infected individuals receiving antiretroviral drugs.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / immunology
  • Adjuvants, Immunologic / therapeutic use
  • Cytokines / therapeutic use
  • Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • HIV Infections / drug therapy
  • HIV Infections / immunology*
  • HIV-1
  • Humans
  • In Vitro Techniques
  • Interferon-gamma / therapeutic use
  • Macrophages / drug effects
  • Macrophages / immunology
  • Models, Immunological
  • Monocytes / drug effects
  • Monocytes / immunology
  • Phagocytosis* / drug effects
  • Receptors, Complement / metabolism
  • Receptors, IgG / metabolism
  • Recombinant Proteins
  • Signal Transduction

Substances

  • Adjuvants, Immunologic
  • Cytokines
  • Receptors, Complement
  • Receptors, IgG
  • Recombinant Proteins
  • Interferon-gamma
  • Granulocyte-Macrophage Colony-Stimulating Factor